胶原酶治疗掌腱膜挛缩症后的并发症
Complications Following Collagenase Treatment for Dupuytren Contracture.
作者信息
Wozniczka Jennifer, Canepa Clifford, Mirarchi Adam, Solomon Joel S
机构信息
1 Oregon Health & Science University, Portland, USA.
2 The Oregon Clinic, Portland, USA.
出版信息
Hand (N Y). 2017 Sep;12(5):NP148-NP151. doi: 10.1177/1558944717711461. Epub 2017 Jun 21.
BACKGROUND
Collagenase Clostridium histolyticum (CCH) injection and manipulation is a relatively new method for treating Dupuytren contracture that is growing in popularity. Although side effects such as swelling and ecchymosis are common, they are typically mild and self-limited. Major complications are rare but have included flexor tendon rupture and complex regional pain syndrome.
METHODS
This study describes a case report of 2 patients seen at our institution.
RESULTS
Here, we report 2 patients seen at our institution each with different, yet serious complications after CCH injection and manipulation. One patient had extensive skin loss and chose amputation over reconstruction. The other patient had loss of perfusion and required finger amputation.
CONCLUSIONS
Although it is unclear how directly the administration of CCH is connected to the observed complications, physicians should recognize the potential for serious rare complications in any treatment of Dupuytren contracture.
背景
注射及操作溶组织梭状芽孢杆菌胶原酶（CCH）是一种治疗掌腱膜挛缩症的相对较新的方法，且越来越受欢迎。虽然肿胀和瘀斑等副作用很常见，但通常较轻微且具有自限性。严重并发症很少见，但包括屈肌腱断裂和复杂性区域疼痛综合征。
方法
本研究描述了在我们机构就诊的2例患者的病例报告。
结果
在此，我们报告在我们机构就诊的2例患者，他们在接受CCH注射及操作后均出现了不同但严重的并发症。1例患者出现大面积皮肤缺损，选择截肢而非重建。另1例患者出现灌注丧失，需要进行手指截肢。
结论
虽然尚不清楚CCH的给药与所观察到的并发症之间的直接关联程度，但医生在掌腱膜挛缩症的任何治疗中都应认识到存在严重罕见并发症的可能性。
Zotero 插件